Aclaris Therapeutics
Aclaris Therapeutics' revenue fell 58.2% to $8 million in fiscal 2025. Its operating margin was −975.9%, down from −758.2% a year earlier. Free cash flow was −$47 million. The diluted share count rose 58.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Aclaris Therapeutics does
Aclaris Therapeutics is a clinical-stage drug developer, meaning its medicines are still being tested in people and none is approved for sale. It focuses on diseases caused by an overactive immune system, such as inflammatory and allergic conditions.
It works on two kinds of medicines. The first are antibodies, which are made-in-the-lab proteins that block a specific signal. These include bosakitug, which targets a protein called TSLP, and ATI-052, which targets two signals at once. The second are small-molecule pills built with its KINect platform, a library and set of tests for finding drugs that block enzymes called kinases. These include ATI-2138, aimed at an enzyme called ITK, and a related drug, ATI-9494.
Aclaris has no product sales to report from these drugs. It says it is looking for partners to develop, win approval for or sell its drug candidates, and it may also license in or buy other candidates to add to its pipeline.
Its biggest risks, as it describes them
- It has lost money since it started, expects more losses and may never be profitable.
- It will need a lot more funding, and may have to cut its plans if it cannot raise it.
- Its drug candidates may fail in testing or fail to win approval, or it may not find partners to develop them.
- It relies heavily on outside companies for clinical trials, manufacturing and development support.
- It has limited information about candidates that are covered by partnership agreements.
Income statement
Aclaris Therapeutics lost money in fiscal 2025: a net loss of $65 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 226 | 230 | 182 | 204 | 151 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 8.9x | 10.6x | 4.2x | 4.0x | 3.4x |
| Quick ratio | 8.9x | 10.6x | 4.2x | 4.0x | 3.4x |
Cash flow
Projections
Project Aclaris Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Aclaris Therapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −249.8% | −148.0% | −661.6% |
| Altman Z'' | −8.69 | −12.36 | −18.21 |
| Accruals ratio | −4.5% | −53.6% | −9.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put Aclaris Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | |
| Xenon Pharmaceuticals | FY25 | — | −4,974.3% | −3,732.2% | — | — | — | Compare |
| Ovid Therapeutics | FY25 | 1,181.3% | −585.2% | −528.6% | — | — | — | Compare |
| Immunome | FY25 | −23.2% | −3,228.8% | −2,890.1% | — | — | — | Compare |
| Precigen | FY25 | 146.7% | −1,141.1% | −927.6% | — | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | 2 | 6 | 4 | 6 | 7 | 30 | 31 | 19 | 8 |
| Revenue growth | — | — | 265.5% | −31.3% | 53.4% | 4.3% | 340.1% | 5.0% | −40.1% | −58.2% |
| Gross profit | — | 0 | 3 | 0 | 1 | 2 | 26 | 28 | 16 | 6 |
| Research and development | 34 | 36 | 61 | 64 | 29 | 44 | 78 | 98 | 34 | 53 |
| Operating income | −49 | −54 | −85 | −111 | −51 | −90 | −90 | −97 | −142 | −76 |
| Net income | −48 | −68 | −133 | −161 | −51 | −91 | −87 | −88 | −132 | −65 |
| Diluted EPS (US$) | −2.25 | −2.44 | −4.03 | −3.90 | −1.20 | −1.60 | −1.33 | −1.27 | −1.71 | −0.53 |
| Diluted shares (millions) | 21 | 28 | 33 | 41 | 42 | 57 | 65 | 70 | 77 | 123 |
| Cash flow | ||||||||||
| Cash from operations | −35 | −55 | −101 | −96 | −39 | −52 | −68 | −78 | −20 | −47 |
| Capital expenditure | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 |
| Free cash flow | −35 | −56 | −102 | −98 | −39 | −52 | −68 | −80 | −20 | −47 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 6 | 14 | 20 | 16 | 11 | 14 | 15 | 20 | 11 | 12 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 174 | 209 | 168 | 75 | 54 | 226 | 230 | 182 | 204 | 151 |
| Debt incl. finance leases | — | — | 30 | — | 11 | — | — | — | — | — |
| Total assets | 176 | 244 | 276 | 98 | 71 | 251 | 255 | 197 | 220 | 160 |
| Total liabilities | 7 | 18 | 60 | 28 | 33 | 54 | 57 | 40 | 65 | 57 |
| Shareholders' equity | 170 | 225 | 215 | 70 | 38 | 197 | 198 | 157 | 156 | 103 |
| Margins and ratios | ||||||||||
| Gross margin | — | 28.3% | 52.7% | 4.1% | 20.8% | 30.3% | 86.5% | 89.0% | 85.1% | 73.3% |
| Operating margin | — | −3,230.0% | −1,378.3% | −2,627.3% | −785.4% | −1,327.1% | −302.0% | −311.6% | −758.2% | −975.9% |
| Net margin | — | −4,071.5% | −2,158.0% | −3,817.2% | −787.0% | −1,344.0% | −292.1% | −283.1% | −705.5% | −829.6% |
| Free cash flow margin | — | −3,321.3% | −1,661.0% | −2,319.8% | −603.0% | −775.6% | −229.1% | −254.8% | −107.9% | −603.4% |
| Rule of 40 (growth + FCF margin) | — | — | −1,395.5% | −2,351.1% | −549.6% | −771.4% | 110.9% | −249.8% | −148.0% | −661.6% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −36.7% | −34.7% | −60.3% | −113.2% | −94.9% | −77.3% | −44.0% | −49.9% | −84.5% | −50.2% |
| Return on assets | −35.6% | −32.7% | −51.1% | −86.3% | −60.3% | −56.4% | −34.4% | −39.1% | −63.2% | −34.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |